The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
NCT03162562 is a phase 1 interventional trial sponsored by CanariaBio Inc.. As of 21 Nov 2026, it was terminated. It studies Oregovomab and Poly ICLC in Cancer of Ovary, Neoplasms, Ovarian and 4 more conditions. The registry lists an enrollment of 10 participants at 2 sites in 1 country. The registry lists a start date of 30 May 2017 and a primary completion date of 5 Nov 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03162562 |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | CanariaBio Inc. |
| Enrollment | 10 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovarian Cancer Stage IV and Ovary Cancer |
| Drugs | Oregovomab and Poly ICLC |
| Start | 30 May 2017 |
| Primary completion | 5 Nov 2020 |
| Study completion | 5 Nov 2020 |
| Last update posted | 22 Dec 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christopher Nicodemus, MD FACP
AIT Strategies
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Hospital Cancer Institute
Orlando
- Vcu Massey Cancer Center, Dalton Oncology Clinic
Richmond
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03162562
Each answer restates registry values shown on this page.
What is NCT03162562?
NCT03162562 is a phase 1 interventional trial sponsored by CanariaBio Inc.. It studies Oregovomab and Poly ICLC in Cancer of Ovary, Neoplasms, Ovarian and 4 more conditions.
Who leads NCT03162562?
The registry names Christopher Nicodemus, MD FACP (study director, AIT Strategies) as the overall official.
Where does NCT03162562 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03162562 study?
The registered drug and biological interventions are Oregovomab and Poly ICLC.
When did NCT03162562 end?
The registry lists a primary completion date of 5 Nov 2020 and a study completion date of 5 Nov 2020. The sponsor last updated the record on 22 Dec 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.